Sales AI gives B2B sales teams the agility, insights, and visibility they need to overcome market instability and close deals ...

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a ...

Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ETCompany ParticipantsAlex Durkee – Investor RelationsJamie Welch ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...

Q1 2025 Earnings Call Transcript May 7, 2025 Operator: Good morning, and welcome to Cadre Holdings First Quarter 2025 Conference Call. Today’s call is being recorded. All lines have been placed on ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Recursion said it will end development for four of its 11 pipeline programs—one of ... is a disciplined way of continuing on high-impact opportunities across these therapeutic areas ...

Desjardins Securities analyst Brent Stadler initiated coverage of three well-known Canadian utility companies on Tuesday.

ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2025, and provided a business update.